Page 123 - 《中国药房》2020年22期
P. 123

252例心力衰竭住院患者沙库巴曲缬沙坦的用药分析                                                         Δ



        孙 莹 ,顾永丽,孙增先(南京医科大学康达学院第一附属医院药学部,江苏 连云港 222000)
                              #
              *
        中图分类号 R972 .9;R969.3        文献标志码 A          文章编号     1001-0408(2020)22-2801-05
                       +
        DOI  10.6039/j.issn.1001-0408.2020.22.20
        摘  要   目的:分析心力衰竭住院患者沙库巴曲缬沙坦的用药情况。方法:收集我院2019年10月-2020年3月使用沙库巴曲缬
        沙坦的住院心力衰竭患者的资料,包括其基本信息,如性别、年龄、住院科室、住院时间等;汇总其沙库巴曲缬沙坦使用情况(包括
        适应证、禁忌证、用法用量、用药疗程)、与血管紧张素转化酶抑制剂(ACEI)/血管紧张素Ⅱ受体拮抗剂(ARB)类药物的转换、药物
        不良反应等信息。结果:共收集到252例患者的资料,其中男性172例(68.25%)、女性80例(31.75%);平均年龄为(67.02±14.23)
        岁,有85例(33.73%)的年龄≥75岁;平均住院时间为(12.03±8.19)d,用药前平均左室射血分数(LVEF)为(38.69±10.45)%,平均
        血钾水平为(4.16±0.65)mmol/L,平均肾小球滤过率估计值(eGFR)为(69.14±32.01)mL/(min·1.73 m)。分布科室以心内科
                                                                                         2
       (59.14%)为主,其次为肾内科(8.73%)、呼吸科(7.14%)、心外科(5.95%)、老年科(5.56%)、急诊内科(3.57%)和神经内科(3.17%)。
        所有患者均有用药适应证,但有25例(9.92%)存在用药禁忌证,其中6例(2.38%)为血钾>5.4 mmol/L、19例(7.54%)为eGFR<15
                    2
        mL/(min·1.73 m)。用法用量以50 mg,bid为主(45.24%);39例(15.47%)给药频次为qd,为不合理给药;平均疗程为(7.80±5.86)
        d。有7例患者(2.78%)与ACEI转换,其中3例患者(42.86%)的转换间隔时间未达36 h;20例患者(7.93%)与ARB转换,均无明
        显转换不适宜情况。14例患者(5.56%)出现低血压,其中2例经停药、12例经减少用药剂量后,血压均恢复至正常范围内;所有患
        者均未出现高血钾、血管神经性水肿、肾功能损害、不自主肌肉颤动和心律失常等不良反应。结论:我院心力衰竭住院患者使用沙
        库巴曲缬沙坦均有用药适应证,且安全性良好,仅有少数患者出现血压不耐受情况;但存在给药剂量偏小、给药频次不适宜、禁忌
        证用药、药物转换时机不适宜等情况。临床药师可开展合理用药知识宣讲,加强对患者的药学监护,及时发现不合理用药情况并
        监测不良反应,同时积极干预,以确保患者用药的合理性及安全性。
        关键词 血管紧张素受体-脑啡肽酶抑制剂;沙库巴曲缬沙坦;心力衰竭;住院患者;合理用药;安全性


        Analysis of the Use of Sacubitril-valsartan in 252 Inpatients with Heart Failure
        SUN Ying,GU Yongli,SUN Zengxian(Dept. of Pharmacy,the First Affiliated Hospital of Kangda College of
        Nanjing Medical University,Jiangsu Lianyungang 222000,China)

        ABSTRACT    OBJECTIVE:To analyze the situation of inpatients with heart failure taking sacubitril-valsartan. METHODS:The
        data of heart failture inpatients using sacubitril-valsartan in our hospital were collected during Oct. 2019 to Mar. 2020,including
        basic information of patients such as gender,age,inpatient department,length of stay;the application of sacubitril-valsartan,
        including indications,contraindications,usage and dosage,course of medication;conversion with angiotensin converting enzyme
        inhibitor(ACEI)/angiotensin Ⅱ receptor antagonist(ARB)and adverse drug reactions,were summarized. RESULTS:A total of
        252 cases were collected,including 172 males(68.25%)and 80 females(31.75%). The average age of the patients was(67.02±
        14.23)years old,and 85 cases were 75 years or older(33.73%). Average hospitalization time was(12.03±8.19)d,the average
        left ventricular ejection fraction(LVEF)before medication was(38.69±10.45)%,the average blood potassium was(4.16±0.65)
                                                                                             2
        mmol/L,and the average estimated value of glomerular filtration(eGFR)was(69.14±32.01)mL/(min·1.73 m). The main distri-
        bution departments were cardiology department(59.14%),followed by nephrology department(8.73%),respiration department
       (7.14%),cardiac surgery department(5.95%),geriatrics department(5.56%),emergency medicine department(3.57%)and
        neurology department(3.17%). All patients had indications,but 25 cases(9.92%)had contraindications,6 cases(2.38%)had
        blood potassium>5.4 mmol/L,19 cases (7.54%) had eGFR<15 mL/(min·1.73 m). The usage and dosage was 50 mg/bid
                                                                          2
       (45.24%);39 cases(15.47%)were given medicine once a day,which was unreasonable. Average treatment course was(7.80±
        5.86)d. 7 patients(2.78%)converted to ACEI,and 3 patients(42.86%)had a conversion interval less than 36 h;20 patients
       (7.93%) were converted to ARB,and there was no obvious inappropriate conversion. Hypotension occurred in 14 patients
                                                           (5.56%). Blood pressure returned to the normal range in 2
           Δ 基金项目:江苏省科技基础设施建设计划(No.BM2018545)
                                                           patients after drug withdrawal and 12 patients after dose
           *主管药师,硕士。研究方向:心血管临床药学。电话:0518-
        85605283。E-mail:471071207@qq.com                   reduction.  No  patient  had  adverse  reactions  such  as
           # 通信作者:主任药师,博士。研究方向:临床药学。电话:0518-               hyperkalemia, angioneuro  edema, renal  impairment,
        85605283。E-mail:sunzx715@163.com                   involuntary muscle tremor and arrhythmia. CONCLUSIONS:


        中国药房    2020年第31卷第22期                                            China Pharmacy 2020 Vol. 31 No. 22  ·2801 ·
   118   119   120   121   122   123   124   125   126   127   128